KR20240074940A - Compositon comprising Liriope platyphylla as an active ingredient for improving and treating dementia disease - Google Patents
Compositon comprising Liriope platyphylla as an active ingredient for improving and treating dementia disease Download PDFInfo
- Publication number
- KR20240074940A KR20240074940A KR1020220151526A KR20220151526A KR20240074940A KR 20240074940 A KR20240074940 A KR 20240074940A KR 1020220151526 A KR1020220151526 A KR 1020220151526A KR 20220151526 A KR20220151526 A KR 20220151526A KR 20240074940 A KR20240074940 A KR 20240074940A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- dementia
- extract
- mixed extract
- food composition
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 46
- 239000004480 active ingredient Substances 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 10
- 241001532026 Liriope muscari Species 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 107
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 49
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 48
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 48
- 235000009120 camo Nutrition 0.000 claims abstract description 48
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 48
- 239000011487 hemp Substances 0.000 claims abstract description 48
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 31
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 30
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 29
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 29
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 28
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 28
- 235000013976 turmeric Nutrition 0.000 claims abstract description 28
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 18
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 18
- 229940010454 licorice Drugs 0.000 claims abstract description 18
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 235000013305 food Nutrition 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 11
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 11
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 240000002045 Guettarda speciosa Species 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 244000268590 Euryale ferox Species 0.000 claims description 5
- 235000006487 Euryale ferox Nutrition 0.000 claims description 5
- 244000061520 Angelica archangelica Species 0.000 abstract description 21
- 230000015654 memory Effects 0.000 abstract description 11
- 210000002569 neuron Anatomy 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract 1
- 241001247821 Ziziphus Species 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 22
- 239000004615 ingredient Substances 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- 230000036541 health Effects 0.000 description 17
- 241000202807 Glycyrrhiza Species 0.000 description 15
- 235000013376 functional food Nutrition 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 208000024827 Alzheimer disease Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 7
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 7
- 229940124595 oriental medicine Drugs 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 7
- 229960002646 scopolamine Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000003920 cognitive function Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 241000405414 Rehmannia Species 0.000 description 3
- 244000057214 Stachys sieboldii Species 0.000 description 3
- 235000005116 Stachys sieboldii Nutrition 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 235000018865 Angelica gigas Nutrition 0.000 description 2
- 240000001810 Angelica gigas Species 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241001080798 Polygala tenuifolia Species 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000010460 hemp oil Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 230000006993 memory improvement Effects 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000011302 passive avoidance test Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XWGPGHFOSMOFBV-SISVZPDLSA-N 2-[2-(2,6-dichloroanilino)phenyl]acetic acid;methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl.CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC XWGPGHFOSMOFBV-SISVZPDLSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 235000013073 Acorus gramineus Nutrition 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000218235 Cannabaceae Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000533367 Cnidium officinale Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 206010053141 Oligodipsia Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 208000026349 Vascular skin disease Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000001215 curcuma longa l. root Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229940042269 diclofenac / misoprostol Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 231100000551 menstrual abnormality Toxicity 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초로 이루어진 혼합 추출물을 유효성분으로 포함하는 치매 예방 또는 개선용 조성물에 관한 것으로, 기억력을 증진시키고 신경세포를 보호하여 치매를 예방, 개선 또는 치료할 수 있다.The present invention relates to a composition for preventing or improving dementia, comprising as an active ingredient a mixed extract of Maekmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice, which improves memory. It can prevent, improve or treat dementia by promoting and protecting nerve cells.
Description
본 발명은 맥문동을 유효성분으로 포함하는 치매 개선 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 치매 예방 또는 개선용 식품 조성물 또는 치매 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a composition for the improvement or treatment of dementia containing MacMoondong as an active ingredient, and more specifically, to a food composition for the prevention or improvement of dementia or a pharmaceutical composition for the prevention or treatment of dementia.
우리나라는 인구의 고령화로 인하여 치매 유병률 또한 급속도로 증가하고 있다. 이에 따라 치매 위험성에 대한 경각심 또한 높아지고 있다. 특히 치매는 서서히 증상이 진행되기 때문에 조기에 병원을 찾아 정확한 진단을 받을 경우 충분한 호전 가능성이 있음에도 많은 사람들이 치료시기를 놓치고 단시간에 중증 치매증상으로 발전하기 쉬워 이는 삶의 질이 급격히 떨어지는 것은 물론 가족들까지도 매우 큰 영향을 끼쳐 사회적 문제로 대두되고 있다.In Korea, the prevalence of dementia is rapidly increasing due to the aging population. Accordingly, awareness of the risk of dementia is also increasing. In particular, since the symptoms of dementia progress slowly, there is a good chance of improvement if you visit a hospital early and receive an accurate diagnosis. However, many people miss treatment and are prone to develop severe dementia symptoms in a short period of time, which not only drastically reduces the quality of life but also reduces the quality of life for family members. It is also having a huge impact on people and is emerging as a social problem.
치매 환자의 약 70%는 알츠하이머성 치매 환자로 알려져 있으며, 수많은 연구들이 진행되면서 알츠하이머에 관여하는 단백질들이 발견되고는 있으나 그 발병 원인은 아직 명확히 알려지지는 않은 상태이다. Approximately 70% of dementia patients are known to have Alzheimer's disease, and as numerous studies are conducted, proteins involved in Alzheimer's disease are being discovered, but the cause of the disease is not yet clearly known.
J Korean Neuropsychiatr Assoc 2018;57(1):30-42 “알츠하이머 치매 약물치료의 현황과 미래”에 기고된 내용을 보면, 종래 알츠하이머 치매의 인지증상 개선을 위한 약물로서 콜린 분해효소 억제제, 메만틴 및 항산화물질이 사용되고 있으며, 콜린 분해효소 억제제는 콜린 분해효소를 억제함으로써 시냅스에서 가용한 아세틸콜린의 양을 증가시키는 기전으로 작용하는데 환자의 인지증상 호전에 어느 정도 도움이 되는 것으로 알려져 있고, 메만틴은 뇌 피질과 해마의 신경세포들의 주된 흥분성 아미노산 신경 전달물질인 글루타메이트는 NMDA 수용체를 활성화시키며 학습과 기억 기능에 관여하고 경증보다는 중증의 알츠하이머에 효능을 보이는 것으로 알려져 있다. 그러나 항산화물질에 대해 단가아민 산화효소 억제제인 셀레길린(selegiline)이나 비타민 E(tocopherol)의 항산화 효과가 알츠하이머 치매 환자의 악화를 막는 데에 도움이 되는가를 보기 위한 연구들이 수행되었으나, 그 결과는 일관성 있는 결론을 내리기 어려웠다. J Korean Neuropsychiatr Assoc 2018;57(1):30-42 According to the article “Current Status and Future of Drug Treatment for Alzheimer’s Dementia,” cholinesterase inhibitors, memantine, and Antioxidants are used, and choline enzyme inhibitors act as a mechanism to increase the amount of acetylcholine available at the synapse by inhibiting choline enzyme inhibitors. It is known to be helpful to some extent in improving the patient's cognitive symptoms, and memantine Glutamate, the main excitatory amino acid neurotransmitter of neurons in the brain cortex and hippocampus, activates NMDA receptors and is involved in learning and memory functions, and is known to be effective in treating severe rather than mild Alzheimer's disease. However, studies have been conducted to determine whether the antioxidant effects of monoamine oxidase inhibitors selegiline or vitamin E (tocopherol) help prevent the deterioration of Alzheimer's dementia patients, but the results are inconsistent. It was difficult to come to a definitive conclusion.
한편, 임상시험 근거가 미약하지만 현실적으로 사용되고 있는 약물로서는 에스트로겐, 항염증 약물, 은행잎 추출물 등이 있다. 이 중 항염증 약물은 아밀로이드가 염증 반응을 유발하고, 미세아교세포를 활성화시키며, 사이토카인 분비를 촉진시킨다고 알려져 연구되었으며, 비스테로이드성 항염증 약물 복용시 알츠하이머 치매 발병 위험을 낮춘다는 역학 연구들도 있었다. Meanwhile, drugs that have weak clinical trial evidence but are actually used include estrogen, anti-inflammatory drugs, and ginkgo biloba extract. Among these, anti-inflammatory drugs have been studied as it is known that amyloid causes an inflammatory response, activates microglia, and promotes cytokine secretion. Epidemiological studies also show that taking non-steroidal anti-inflammatory drugs lowers the risk of developing Alzheimer's dementia. there was.
그러나 placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999;53:197-201 등에 개시된 바에 따르면, 임상시험 결과 아스피린을 포함한 여러가지 항염증 약물들이 알츠하이머 치매의 인지 저하를 막지 못하는데다 약물 부작용이 더 흔하고, Cox-2 억제제의 경우 심혈관계 부작용의 위험성마저 있어 항염증 약물은 알츠하이머 치매의 예방이나 치료에 적합하지 않음을 확인할 수 있다.However, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. According to Neurology 1999;53:197-201, etc., clinical trial results show that various anti-inflammatory drugs, including aspirin, do not prevent cognitive decline in Alzheimer's dementia, and drug side effects are more common, and in the case of Cox-2 inhibitors, there is a risk of cardiovascular side effects. It can be confirmed that anti-inflammatory drugs are not suitable for preventing or treating Alzheimer's dementia.
국내에서는 천연물을 이용한 항치매 연구가 활발히 진행되고 있으며 대표적으로 인삼에 대한 연구가 많이 보고되어 있으며 이외에도 동충하초, 감초, 원지 등 많이 약물들이 연구되고 있다. 그러나 이들 천연물의 경우 임상에 적용할 정도로 우수한 효과를 갖는 천연물이 없어, 본 발명에서는 이들 천연물들을 활용하여 뇌기능이나 인지 기능 개선 기능을 갖는 새로운 복합 조성물을 개발하여 본 발명을 완성하였다.In Korea, anti-dementia research using natural products is actively underway, and many studies on ginseng have been reported. In addition, many drugs such as Cordyceps sinensis, licorice root, and Wonji root are being studied. However, in the case of these natural products, there are no natural products with excellent effects that can be applied clinically, so the present invention developed a new complex composition that has the function of improving brain function or cognitive function using these natural products and completed the present invention.
본 발명의 목적은 치매를 예방, 개선 또는 치료할 수 있으며, 한약재인 맥문동을 주재료로 하여 인체에 무해하고 다양한 식품, 음료, 의약으로 제조할 수 있는 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초를 유효성분으로 포함하는 식품 조성물 및 약학 조성물을 제공하는 데 있다.The purpose of the present invention is to prevent, improve or treat dementia, and to use the herbal medicine Macmundong as the main ingredient, which is harmless to the human body and can be manufactured into various foods, beverages, and medicines such as MacMoon-dong, Seokchangpo, Wonji, Baekboksin, Choseokjam, Turmeric, The aim is to provide food compositions and pharmaceutical compositions containing angelica root, hemp seed, jujube, turmeric root, rehmannia root, and licorice root as active ingredients.
본 발명의 하나의 측면에 따르면,According to one aspect of the invention,
맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초로 이루어진 혼합 추출물을 유효성분으로 포함하는 치매 예방 또는 개선용 식품 조성물이 제공된다.A food composition for preventing or improving dementia is provided, containing as an active ingredient a mixed extract of Macmundong, Seokchungpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa, and licorice root.
상기 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것일 수 있다.The extract may be extracted with water, alcohol with 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 식품 조성물은, 혼합 추출물 총 중량에 대하여 15~25 중량% 맥문동, 10~15 중량% 석창포, 5~7 중량% 원지, 5~7 중량% 백복신, 5~7 중량% 초석잠, 5~7 중량% 강황, 5~7 중량% 당귀, 5~7 중량% 햄프시드, 8~10 중량% 대추, 5~7 중량% 천궁, 5~10 중량% 숙지황 및 5~10 중량% 감초로 혼합된 것을 특징으로 하는 것일 수 있다.The food composition contains 15-25% by weight of Macmundong, 10-15% by weight of Seokchangpo, 5-7% by weight of Wonji, 5-7% by weight of Baekboksin, 5-7% by weight of Chosukjam, 5-7% by weight, based on the total weight of the mixed extract. % by weight turmeric, 5-7% by weight angelica, 5-7% by weight hemp seed, 8-10% by weight jujube, 5-7% by weight Cheonggung, 5-10% by weight Rehmannia glutinosa and 5-10% by weight licorice. It may be a feature.
상기 식품 조성물은, 혼합 추출물 100 중량부에 대하여 1 내지 5 중량부의 검실(Euryale ferox Salisbury) 추출물을 더 포함하는 것일 수 있다.The food composition may further include 1 to 5 parts by weight of Euryale ferox Salisbury extract based on 100 parts by weight of the mixed extract.
상기 검실 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것일 수 있다.The gumsil extract may be extracted with water, alcohol with 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 치매는 알츠하이머성 치매일 수 있다.The dementia may be Alzheimer's dementia.
상기 치매 예방 또는 개선용 식품 조성물은 과립제, 산제, 정제, 피복정, 캡슐제, 액제, 시럽, 즙, 현탁제, 유제 및 점적제 중에서 선택된 1종 이상으로 제제화되어 식품에 첨가될 수 있다.The food composition for preventing or improving dementia may be formulated with one or more types selected from granules, powders, tablets, coated tablets, capsules, solutions, syrups, juices, suspensions, emulsions and drops and added to food.
본 발명의 다른 하나의 측면에 따르면,According to another aspect of the present invention,
맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초로 이루어진 혼합 추출물을 유효성분으로 포함하는 치매 예방 또는 치료용 약학 조성물이 제공된다.A pharmaceutical composition for the prevention or treatment of dementia is provided, containing as an active ingredient a mixed extract of Macmundong, Seokchungpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa, and licorice root.
상기 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것일 수 있다.The extract may be extracted with water, alcohol with 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 약학 조성물은, 혼합 추출물 총 중량에 대하여 15~25 중량% 맥문동, 10~15 중량% 석창포, 5~7 중량% 원지, 5~7 중량% 백복신, 5~7 중량% 초석잠, 5~7 중량% 강황, 5~7 중량% 당귀, 5~7 중량% 햄프시드, 8~10 중량% 대추, 5~7 중량% 천궁, 5~10 중량% 숙지황 및 5~10 중량% 감초로 혼합된 것을 특징으로 하는 것일 수 있다.The pharmaceutical composition contains 15-25% by weight Macmundong, 10-15% by weight Seokchangpo, 5-7% by weight Wonji, 5-7% by weight Baekboksin, 5-7% by weight Chosukjam, 5-7% by weight, based on the total weight of the mixed extract. % by weight turmeric, 5-7% by weight angelica, 5-7% by weight hemp seed, 8-10% by weight jujube, 5-7% by weight Cheonggung, 5-10% by weight Rehmannia glutinosa and 5-10% by weight licorice. It may be a feature.
상기 약학 조성물은, 혼합 추출물 100 중량부에 대하여 1 내지 5 중량부의 검실(Euryale ferox Salisbury)을 더 포함하는 것일 수 있다.The pharmaceutical composition may further include 1 to 5 parts by weight of Euryale ferox Salisbury based on 100 parts by weight of the mixed extract.
상기 검실 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것일 수 있다.The gumsil extract may be extracted with water, alcohol with 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 치매는 알츠하이머성 치매일 수 있다.The dementia may be Alzheimer's dementia.
상기 치매 예방 또는 치료용 약학 조성물은 과립제, 산제, 정제, 피복정, 캡슐제, 액제, 시럽, 즙, 현탁제, 유제 및 점적제 중에서 선택된 1종 이상으로 제제화될 수 있다.The pharmaceutical composition for preventing or treating dementia may be formulated with one or more types selected from granules, powders, tablets, coated tablets, capsules, solutions, syrups, juices, suspensions, emulsions and drops.
본 발명의 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초로 이루어진 혼합 추출물을 유효성분으로 포함하는 식품 조성물 및 약학 조성물은 기억력을 증진시키고 신경세포를 보호하여 치매를 예방, 개선 또는 치료할 수 있으며 한약재료를 유효성분으로 하여 인체에 무해하고 다양한 식품, 의약으로 제조할 수 있다.Food compositions and pharmaceutical compositions containing as active ingredients a mixed extract of Macmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice root of the present invention improve memory and nerve cells. It can prevent, improve or treat dementia by protecting the body, and using herbal medicine ingredients as active ingredients, it is harmless to the human body and can be manufactured into various foods and medicines.
도 1은 실험군 1, 2 및 비교군의 수동회피실험 결과 그래프이다.
도 2는 실험군 1, 2 및 비교군의 수중미로시험 결과 그래프이다. Figure 1 is a graph of the results of a passive avoidance experiment for experimental groups 1 and 2 and a comparison group.
Figure 2 is a graph of the water maze test results of experimental groups 1 and 2 and comparison groups.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 치매 예방, 치료 또는 개선용 조성물은 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초로 이루어진 혼합 추출물을 유효성분으로 포함한다.The composition for preventing, treating or ameliorating dementia of the present invention contains as an active ingredient a mixed extract consisting of Maekmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice root.
본 발명의 조성물은 상기 유효성분을 포함하는 치매 예방 또는 개선용 식품 조성물 또는 치매 예방 또는 치료용 약학 조성물을 제공한다.The composition of the present invention provides a food composition for preventing or improving dementia or a pharmaceutical composition for preventing or treating dementia containing the above active ingredients.
상기 추출물을 추출하는 추출용매는 물, 탄소수 1 내지 4의 저급알코올, 에틸렌글리콜, 에틸에테르 또는 이들의 혼합용매이다. 상기 저급알코올로는 20 내지 80%의 메탄올, 에탄올, 부탄올 또는 프로판올을 들 수 있다.The extraction solvent for extracting the extract is water, lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. The lower alcohol may include 20 to 80% methanol, ethanol, butanol, or propanol.
본 발명에서의 '맥문동(Liriope platyphylla)'은 다년생식물로서 근경과 종자로 번식하는 식물로서 우리나라에서는 표고가 500 m 이하의 낮은 야산에서 주로 분포하고 있으며, 잎은 연중 녹색을 유지한다. 뿌리줄기는 굴고 딱딱하며, 뿌리는 가늘지만 강하고, 수염뿌리 끝이 땅콩처럼 굵어지는 것이 있다. 꽃은 5~6월에 피며, 꽃덮이는 6개, 연한 자줏빛이다. 열매는 얇은 껍질이 벗겨지면서 검은색 종자가 노출된다. 약재는 방추형으로 길이 10~25 mm, 지름 3~5 mm이다. 한쪽 끝은 뽀족하고 다른 쪽은 둥글게 되어 있다. 바깥면은 황색~엷은 황갈색이며 크고 작은 세로주름이 있다. 피층은 부드러우며 무르고 중심주는 질겨서 꺽기 어렵다. 여름철에 채취하여 햇별에 말려 사용한다. 맥문동은 한국과 중국에서 기침, 가래 등의 질병 치료제로 한방에서 주로 사용되어져 왔으며, 최근에는 당뇨 치료, 기억력 증진, 미생물 억제, 염증 억제 등의 기능이 알려지면서 많은 연구가 진행되고 있다.In the present invention, 'Liriope platyphylla' is a perennial plant that propagates by rhizomes and seeds. In Korea, it is mainly distributed in low mountainous areas with an altitude of 500 m or less, and its leaves remain green throughout the year. The rhizome is curved and hard, the roots are thin but strong, and the ends of the fibrous roots are as thick as peanuts. Flowers bloom from May to June, have 6 perianths, and are light purple. The thin skin of the fruit peels off, exposing the black seeds. The medicinal material is spindle-shaped, 10 to 25 mm long and 3 to 5 mm in diameter. One end is pointed and the other is rounded. The outer surface is yellow to light tan and has large and small vertical wrinkles. The skin layer is soft and soft, and the center is tough and difficult to break. It is collected in the summer and dried in the sun before use. Macmundong has been mainly used in oriental medicine in Korea and China as a treatment for diseases such as cough and phlegm, and recently, many studies are being conducted as its functions such as treating diabetes, improving memory, suppressing microorganisms, and suppressing inflammation are known.
본 발명에서의 '석창포(Acorus gramineus)'는 사철 푸른 잎을 가진 여러해살이 풀로, 남부의 따뜻한 고장과 제주도에 주로 분포하며, 산지나 들판의 냇가에서 나는데 습한 바위틈에 붙어산다. 석창포는 뿌리줄기를 주로 약재로 쓰며, 호흡조절, 원활한 혈액 순환 등에 효능이 있는 것으로 알려져 있다.'Acorus gramineus' in the present invention is a perennial herb with green leaves all year round, and is mainly distributed in the warm regions of the south and Jeju Island. It grows in streams in mountains or fields and lives in moist rock crevices. The rhizome of Seokchangpo is mainly used as a medicine, and is known to be effective in controlling breathing and smooth blood circulation.
본 발명에서의 '원지(Polygala tenuifolia)'는 쌍떡잎식물 무환자나무목 원지과의 여러해살이풀로, 우리나라 중부 이북의 낮은 산 양지 쪽에서 자라며, 주로 가을이나 봄에 뿌리를 캐 물에 씻은 다음 목질부를 뽑아버리고 햇볕에 말려 사용한다. 원지는 진정작용, 최면작용, 강심작용, 가래삭임작용, 용혈작용 등에 효능이 있는 것으로 알려져 있다.'Polygala tenuifolia' in the present invention is a perennial herb of the dicotyledonous plant Polygala tenuifolia family. It grows on the sunny side of low mountains north of central Korea. Mainly in the fall or spring, the roots are dug up and washed in water, then the xylem is pulled out and exposed to sunlight. Use after drying. It is known to have sedative, hypnotic, cardiotonic, phlegm-reducing, and hemolytic effects.
본 발명에서의 '백복신(Poria Cocos)'은 구멍쟁이 버섯과(Polyporaceae)에 속한 진균인 복령(Poria cocos(SCHW.) WOLF)의 균핵 중에서 가운데 송근(松根)이 있는 것을 건조한 것으로서, 한방에서는 주로 정신을 안정시키고 머리를 맑게하는데 사용되는 것으로 알려져 있다.'Poria Cocos' in the present invention is dried sclerotia with a root in the middle of Poria cocos (SCHW.) WOLF, a fungus belonging to the Polyporaceae family, and is mainly used in oriental medicine. It is known to be used to calm the mind and clear the mind.
본 발명에서의 '초석잠(Stachys sieboldii Miq.)'은 석잠풀의 뿌리를 제외한 식물체 전체를 지칭하는 약용식물이며, 석잠풀은 떡잎식물로서 통화식물목 꿀풀과의 여러해살이풀로서, 한국, 중국 동북부, 일본, 시베리아 동부, 캄차카 반도 등지의 산과 들의 습지에서 널리 분포하고 크기는 보통 30~60cm이다. 초석잠은 한방에서 미열이 있고, 배뇨가 곤란하며, 몸이 붓는 증세에 효과가 있는 것으로 알려져 있고, 최근의 연구에서 초석잠의 괴경에 뇌경색 또는 신염에 대해 효과적인 악티오사이드라는 성분이 함유되어 있는 것으로 알려져 있다.In the present invention, 'Stachys sieboldii Miq.' is a medicinal plant that refers to the entire plant excluding the roots of Stachys sieboldii, and Stachys sieboldii Miq. is a cotyledonous plant and a perennial herb of the Lamiaceae family, grown in Korea and China. It is widely distributed in the mountains and wetlands of the northeast, Japan, eastern Siberia, and the Kamchatka Peninsula, and is usually 30 to 60 cm in size. It is known in oriental medicine to be effective in treating symptoms of mild fever, difficulty in urinating, and body swelling, and recent studies have shown that its tubers contain an ingredient called actioside, which is effective against cerebral infarction or nephritis. It is known that
본 발명에서의 '강황(Curcuma longa)은 생강목에 속하는 다년생 식물로서 인도를 중심으로 한 열대, 아열대 지역에서 주로 재배되며 줄기와 뿌리를 식용, 약용 등으로 사용된다. 강황의 뿌리줄기는 주로 한약재로 사용되며, 맵고 쓴 맛이 나는 황색의 약재로서, 통증완화와 월경불순에 효능이 있는 것으로 알려져 있다.In the present invention, 'Curcuma longa' is a perennial plant belonging to the ginger family and is mainly cultivated in tropical and subtropical regions, mainly in India, and its stems and roots are used for edible and medicinal purposes. The rhizome of turmeric is mainly used as an herbal medicine. It is a yellow medicinal herb with a spicy and bitter taste and is known to be effective in relieving pain and treating menstrual irregularities.
본 발명에서의 '당귀(참당귀: Angelica gigas Nakai)'는 산형과에 속하는 다년생 풀인 당귀의 뿌리를 말린 것으로서 맛은 달고 매우며 성질은 따뜻하다. 당귀는 빈혈 예방 및 치료에 주로 사용되며, 각종 부인병에 효과가 좋다고 알려져 있다. 'Angelica gigas Nakai' in the present invention is the dried root of Angelica gigas, a perennial herb belonging to the Umbrella family. It has a sweet and very sweet taste and warm properties. Angelica root is mainly used to prevent and treat anemia, and is known to be effective in treating various gynecological diseases.
본 발명에서의 '헴프씨드(Seed of Cannabis sativa L.)'는 삼과의 한해살이풀인 대마의 씨앗으로, 껍질에 있는 환각성분인 THC(Tetrahydrocanabinol)를 제거하여 식용 가능한 상태를 말한다. 원산지는 중앙아시아이며, 현재는 전 세계 다양한 지역에서 재배하고 있다. 헴프씨드는 고소하면서도 부드러운 식감을 가지고 있어 여타의 견과류와 유사한 맛을 나타내며, 단백질, 필수 아미노산 및 미네랄 함량이 높아 영양적으로 우수하며, 지방 함량이 높아(25~35%) 압착, 추출하여 식용유로도 이용되고 있다. 또한, 헴프씨드의 오일은 알파 리놀레산(Alpha-Linolenic Acid; ALA)과 감마 리놀레산 등의 다가 불포화 지방산(Polyunsaturated fatty acid) 등이 풍부하여, 콜레스테롤 감소, 혈관염증 완화, 피부 질환, 아토피 감소 효과가 우수하다고 알려져 있다. 한편, 헴프씨드를 한방에서는 마자인으로 부르며, 난치성 변비, 소갈증, 각종 통증질환, 월경불순, 피부질환 및 이질 등에 사용하는 것으로 알려져 있다.In the present invention, 'Seed of Cannabis sativa L.' refers to the seeds of hemp, an annual plant of the hemp family, and is edible by removing the hallucinogenic ingredient THC (Tetrahydrocanabinol) from the peel. Its origin is Central Asia, and it is currently cultivated in various regions around the world. Hemp seeds have a nutty yet soft texture and taste similar to other nuts. They are nutritious due to their high protein, essential amino acid and mineral contents. They also have a high fat content (25-35%) and are pressed, extracted and used as cooking oil. is also being used. In addition, hemp seed oil is rich in polyunsaturated fatty acids such as alpha-linolenic acid (ALA) and gamma linoleic acid, and is excellent for reducing cholesterol, alleviating vascular inflammation, skin diseases, and atopy. It is known that Meanwhile, hemp seeds are called mazain in oriental medicine, and are known to be used for intractable constipation, hypodipsia, various pain diseases, menstrual irregularities, skin diseases, and dysentery.
본 발명에서의 햄프씨드는 오일성분이 제거된 것을 사용하였다. 상기 오일 성분이 제거된 햄프씨드는 햄프씨드를 헥산으로 추출한 후의 잔사물인 것일 수 있다. 구체적으로, 본 발명의 햄프씨드에 헥산을 첨가하여 실온에서 교반하여 추출한 후, 원심분리하여 상등액(오일 성분)을 제거하고 남은 잔사를 건조하여 얻은 것일 수 있다. 상술한 과정을 통해 오일성분이 제거된 햄프씨드는 '햄프씨드 박'이라고도 한다.In the present invention, hemp seeds from which the oil component was removed were used. Hemp seeds from which the oil component has been removed may be a residue after extracting hemp seeds with hexane. Specifically, hexane may be added to the hemp seeds of the present invention, extracted by stirring at room temperature, then centrifuged to remove the supernatant (oil component), and the remaining residue may be dried. Hemp seeds from which the oil component has been removed through the above-mentioned process are also called 'hemp seed meal'.
본 발명에서 햄프씨드의 오일 성분을 제거하지 않은 것을 사용할 경우에는 체내에서 트롬빈을 활성화하여 혈전 생성을 촉진하는 부작용이 발생할 수 있다.If the hemp seed oil component is used in the present invention without removing the oil component, a side effect may occur that promotes the formation of blood clots by activating thrombin in the body.
본 발명에서의 '대추(Zizyphus jujube Miller)'는 갈매나무과(Rhamnaceae)에 속하는 낙엽활엽교목인 대추나무의 열매로, 페놀성 물질이 풍부한 식품으로 비타민 C의 함량이 높고 노화를 방지하는 효과가 있으며, 뇌출혈과 고혈압의 예방 등 순환기 계통의 건강유지에 그 약리효과가 크다고 알려져 있다. 이러한 대추는 고유의 단맛으로 기호도가 높아 우리 식생활에 깊은 연관이 있으며, 가공식품 제조 시 관능적 특성을 상승시켜주는 것으로 알려져 있다.'Zizyphus jujube Miller' in the present invention is the fruit of the jujube tree, a deciduous tree belonging to the Rhamnaceae family. It is a food rich in phenolic substances, has a high content of vitamin C, and has an anti-aging effect. It is known to have a significant pharmacological effect in maintaining the health of the circulatory system, such as preventing cerebral hemorrhage and high blood pressure. These jujubes are highly preferred due to their inherent sweetness and are deeply related to our eating habits, and are known to increase sensory characteristics when manufacturing processed foods.
본 발명에서의 '천궁(Cnidium officinale)'은 다년생 초본으로 높이가 40-70 cm이고, 식물체에 향기가 나는 특징을 가지고 있다. 천궁 뿌리는 불규칙한 결절상의 덩어리로 직경이 2-7 cm이며, 표면은 황갈색으로 거친 주름이 있고, 평행으로 융기한 윤절이 여러개 있으며, 정상부에는 오목한 원형의 줄기 흔적이 있다. 단면은 황백색 혹은 회황색인데 황갈색의 유실이 산재해 있고, 형성층은 물결모양의 황문을 이룬다. 천궁은 강한 냄새가 있고, 맛은 맵고 조금 쓰며 달다. 한방에서는 보혈, 강장, 진정, 진통 등을 목표로 냉증, 빈혈 및 월경 장해 등 각종 부인병 질환에 쓰인다. 천궁의 뿌리는 불규칙한 결절상의 덩어리로서 직경이 2-7 ㎝이며 표면은 황갈색으로 거친 주름이 있고 평행으로 융기한 윤절이 여러 개 있으며 정상부에는 오목한 원형의 줄기 흔적이 있다. 그 단면은 황백색 혹은 회황색인데 황갈색의 유실이 산재해 있고 형성층은 물결 모양의 황문을 이룬다. 천궁의 뿌리는 한방에서 보혈, 강장, 진정 및 진통 등을 목표로 냉증, 빈혈, 월경 장애 등 각종 부인병 질환에 쓰이는 것으로 알려져 있다.'Cnidium officinale' in the present invention is a perennial herb with a height of 40-70 cm and has the characteristic of having a fragrant plant. The root of the arch is an irregular nodular mass with a diameter of 2-7 cm. The surface is yellow-brown with rough wrinkles, has several parallel raised nodes, and has traces of a concave circular stem at the top. The cross section is yellow-white or gray-yellow, with scattered yellow-brown loss, and the cambium forms wavy yellow gates. Cheongung has a strong smell and tastes spicy, slightly bitter, and sweet. In oriental medicine, it is used for various gynecological diseases such as coldness, anemia, and menstrual disorders with the aim of replenishing blood, tonicity, sedation, and pain relief. The root of the arch is an irregular nodular mass with a diameter of 2-7 cm. The surface is yellow-brown with rough wrinkles, has several parallel raised nodes, and has traces of a concave circular stem at the top. The cross section is yellow-white or gray-yellow, with yellow-brown loss scattered throughout, and the cambium forms wavy yellow gates. The root of Cheongung is known to be used in oriental medicine for various gynecological diseases such as poor circulation, anemia, and menstrual disorders with the aim of replenishing blood, tonicity, sedation, and pain relief.
본 발명에서의 '숙지황(Rehmanniae Radix Preparata)'은 현삼과에 딸린 약용식물의 뿌리를 쪄서 말린 것으로, 한방에서 약재로 사용하고 있으며, 날것을 생지황, 말린 것을 건지황이라 하며, 숙지황 중 특히 술에 담갔다가 쪄서 말리기를 9번 되풀이하여 만든 것은 구지황이라 하여 그 약효를 으뜸으로 친다. 맛은 달면서도 쓴맛이 돌고 따뜻한 성질이 있어 혈을 보(補)하고 정(精 : 생명이 발생하고 활동하는 데 기본이 되는 물질)을 보충해서 허리와 무릎이 시리고 아픈 증상이나 월경이상, 어지럼증 등을 치료하고 머리를 검게 하는 효능이 있는 것으로 알려져 있다.In the present invention, 'Rehmanniae Radix Preparata' is the steamed and dried root of a medicinal plant belonging to the ginseng family, and is used as a medicine in oriental medicine. The raw rehmanniae is called fresh rehmannia, and the dried one is called dried rehmannia, and among ripe rehmanniae, it is especially soaked in alcohol. The product made by repeating steaming and drying nine times is called Gu Rehmannia glutinosa and is considered to have the best medicinal properties. It tastes sweet but has a bitter taste and has a warm nature, so it replenishes blood and essence (a basic substance for the development and activity of life), thereby treating symptoms such as cold and painful back and knees, menstrual abnormalities, dizziness, etc. It is known to be effective in treating and blackening hair.
본 발명에서의 '감초(Glycyrrhiza uralensis)'는 콩과에 속하는 여러해살이풀로 중국 북동부와 시베리아, 몽골, 중국 북부 등지에 분포한다. 뿌리는 건조시켜서 한약재로 사용하는데, 그 맛이 달고, 모든 약물과 배합이 잘 되어 중화작용을 하는 것으로 알려져 있다.'Glycyrrhiza uralensis' in the present invention is a perennial herb belonging to the legume family and is distributed in northeastern China, Siberia, Mongolia, and northern China. The root is dried and used as an herbal medicine. It is known to have a sweet taste, mix well with all drugs, and have a neutralizing effect.
상기 식품 조성물 또는 약학 조성물은, 혼합 추출물 총 중량에 대하여 15~25 중량% 맥문동, 10~15 중량% 석창포, 5~7 중량% 원지, 5~7 중량% 백복신, 5~7 중량% 초석잠, 5~7 중량% 강황, 5~7 중량% 당귀, 5~7 중량% 햄프시드, 8~10 중량% 대추, 5~7 중량% 천궁, 5~10 중량% 숙지황 및 5~10 중량% 감초로 혼합된 것이 바람직하고, 혼합 추출물 총 중량에 대하여 20 중량% 맥문동, 13 중량% 석창포, 6 중량% 원지, 6 중량% 백복신, 6 중량% 초석잠, 6 중량% 강황, 6 중량% 당귀, 6 중량% 햄프시드, 9 중량% 대추, 6 중량% 천궁, 8 중량% 숙지황 및 8 중량% 감초로 혼합된 것이 보다 바람직하다.The food composition or pharmaceutical composition contains 15-25% by weight of Macmundong, 10-15% by weight of Seokchangpo, 5-7% by weight of Wonji, 5-7% by weight of Baekboksin, 5-7% by weight of Chosukjam, based on the total weight of the mixed extract. 5~7% by weight turmeric, 5~7% by weight angelica root, 5~7% by weight hemp seed, 8~10% by weight jujube, 5~7% by weight Cheongung, 5~10% by weight Rehmannia glutinosa and 5~10% by weight licorice. It is preferable that it is mixed, and based on the total weight of the mixed extract, 20% by weight Macmundong, 13% by weight Seokchangpo, 6% by weight Wonji, 6% by weight Baekboksin, 6% by weight Choseokjam, 6% by weight turmeric, 6% by weight Angelica root, 6% by weight. A mixture of % hempseed, 9% jujube, 6% perilla, 8% Rehmannia glutinosa and 8% licorice by weight is more preferred.
특히 혼합 추출물 중에서 원지, 백복신, 초석잠, 강황, 당귀, 햄프씨드 및 천궁의 중량비가 1:1:1:1:1:1:1이고, 숙지황과 감초의 중량비가 1:1인 것이 가장 바람직하다. In particular, among the mixed extracts, it is most desirable that the weight ratio of Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed and Cheongung is 1:1:1:1:1:1:1, and that the weight ratio of Rehmannia glutinosa and Licorice root is 1:1. do.
상기 혼합 추출물의 조성범위를 만족하는 경우, 콜린성 신경 기능의 퇴화 또는 신경세포 사멸에 관여하여 신경세포 보호 효과를 얻을 수 있고, 단기 및 장기 기억력의 감소를 억제하여 치매의 예방, 개선 또는 치료 효과를 달성할 수 있다.If the composition range of the mixed extract is satisfied, a neuronal protective effect can be obtained by participating in the degeneration of cholinergic nerve function or neuronal cell death, and the prevention, improvement or treatment of dementia by suppressing the decline in short-term and long-term memory. It can be achieved.
본 발명에 따른 혼합 추출물은 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초를 상기 중량비로 혼합하여 추출한 혼합 추출물 또는 각각의 추출물을 상기 중량비로 혼합한 혼합물이 사용될 수 있으나, 바람직하게는 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초를 상기 중량비로 혼합하여 추출한 혼합 추출물임을 특징으로 한다.The mixed extract according to the present invention is a mixed extract obtained by mixing Macmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice in the above weight ratio, or mixing each extract in the above weight ratio. A mixture may be used, but it is preferably a mixed extract obtained by mixing Macmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice in the above weight ratio.
상기 혼합 추출물은 당업계에 공지된 방법을 사용하여 천연 또는 가공한 시료로부터 추출, 분리 및 분획하여 수득한 것을 사용할 수 있다. 예를 들어 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초에 해당하는 모든 사용부위를 시료로 사용할 수 있으나, 맥문동은 열매, 석창포는 뿌리와 줄기, 원지는 뿌리, 초석잠은 뿌리를 제외한 식물체 전체, 강황, 당귀, 천궁 및 감초는 뿌리일 수 있으며, 대추는 대추나무의 열매, 햄프씨드는 오일 성분이 제거된 대마의 씨, 숙지황은 현삼과에 딸린 약용식물의 뿌리를 쪄서 말린 것을 시료로 사용할 수 있다.The mixed extract can be obtained by extraction, separation, and fractionation from natural or processed samples using methods known in the art. For example, all parts of Macmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa, and licorice can be used as samples. However, Macmundong is the fruit, and Seokchangpo is the root and stem. , the base can be the root, the root can be the entire plant excluding the root, turmeric, angelica root, turmeric and licorice can be the roots, jujube can be the fruit of the jujube tree, hemp seeds can be the seeds of hemp with the oil component removed, and rehmannia glutinosa can be the ginseng and Steamed and dried roots of medicinal plants can be used as samples.
상기 혼합 추출물을 수득하기 위한 용매로는 물, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등의 탄소수 1 내지 4의 알코올 등을 단독으로 또는 2종 이상 혼합하여 사용할 수 있으며 이에 제한되는 것은 아니나, 더욱 바람직하게는 물 또는 20 내지 80 부피%의 에탄올 수용액을 들 수 있다. 추출방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 다양한 방법이 사용될 수 있다.Solvents for obtaining the mixed extract include water, alcohols with 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, etc., alone or in combination with 2 More than one type can be mixed and used, but is not limited thereto, and more preferably water or a 20 to 80% by volume ethanol aqueous solution. As extraction methods, various methods such as hot water extraction, cold needle extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression can be used.
또한, 상기 혼합 추출물은 당업계에서 알려진 통상의 방법으로 상온에서 냉침, 가열 및 여과하여 액상물을 얻을 수 있으며, 또는 추가로 용매를 증발, 분무 건조 또는 동결건조 할 수도 있다. 또한 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조할 수도 있으며, 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층크로마토그래피(thin layer chromatography), 고성능액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획으로도 얻을 수 있다.In addition, the mixed extract can be obtained as a liquid by immersing, heating, and filtering at room temperature by conventional methods known in the art, or the solvent can be further evaporated, spray dried, or freeze-dried. It can also be manufactured in powder form by additional processes such as reduced pressure distillation and freeze-drying or spray-drying, as well as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography. It can also be obtained as an additional purified fraction using various chromatography methods such as liquid chromatography.
따라서 본 발명에서 사용되는 혼합 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출물, 분획물 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다.Therefore, the mixed extract used in the present invention is a concept that includes all extracts, fractions, and purifications obtained at each stage of extraction, fractionation, or purification, as well as their dilutions, concentrates, or dried products.
상기 식품 조성물은, 혼합 추출물 100 중량부에 대하여 1 내지 5 중량부의 검실(Euryale ferox Salisbury) 추출물을 더 포함하는 것일 수 있다.The food composition may further include 1 to 5 parts by weight of Euryale ferox Salisbury extract based on 100 parts by weight of the mixed extract.
본 발명에서의 '검실(Euryale ferox Salisb)'은 수련과에 속하는 가시연꽃의 씨를 말린 것으로 맛은 달고 성질은 차지도 않고 평하여 비장과 신장을 보하는 작용을 한다. 가시연꽃은 우리나라 중부 이남의 못에 심어 재배하며 가을에 익은열매를 따서 굳은 껍질을 까버리고 햇볕에 말려 사용한다. 상기 검실은 신장 기능을 튼튼히 하고 비, 위장, 소화기 기능을 튼튼히 한다. 스트레스로 생기는 증세를 해소한다. 精氣(정기)를 북돋우며 기억력을 좋게 하고 눈과 귀를 밝게 하는 것으로 알려져 있다.In the present invention, 'Euryale ferox Salisb' is the dried seeds of prickly lotus flower belonging to the water lily family. It has a sweet taste, is not cold, but is flat, and acts to nourish the spleen and kidneys. Thorn lotus is cultivated by planting it in ponds in the central and southern regions of Korea. The ripe fruit is picked in the fall, peeled off the hardened skin, and dried in the sun before use. The gum room strengthens kidney function and strengthens spleen, stomach, and digestive functions. Relieves symptoms caused by stress. It is known to boost vitality, improve memory, and brighten the eyes and ears.
상기 검실 추출물은 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초를 상기 중량비로 혼합하여 추출한 혼합 추출물에 검실로부터 수득된 검실 추출물을 혼합한 것으로써, 상기 검실 추출물은 물, 탄소수 1 내지 4의 저급 알코올, 또는 이들의 혼합용매로 추출된 것일 수 있다. 상기 검실 추출물을 추출하는 추출용매는 특별히 한정하는 것은 아니지만 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매를 들 수 있으며, 바람직하게는 물, 20 내지 80 부피%의 메탄올, 에탄올, 부탄올 또는 프로판올 수용액을 들 수 있고, 더욱 바람직하게는 물 또는 20 내지 80 부피%의 에탄올 수용액을 들 수 있다.The gumsil extract is obtained by mixing the gumsil extract obtained from the gumsil with the mixed extract extracted by mixing Macmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice in the above weight ratio. , the gumsil extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The extraction solvent for extracting the gumsil extract is not particularly limited, but includes water, lower alcohols having 1 to 4 carbon atoms, or mixed solvents thereof, preferably water, 20 to 80% by volume of methanol, ethanol, butanol, or Examples include a propanol aqueous solution, more preferably water or a 20 to 80% by volume ethanol aqueous solution.
본 명세서에서의 용어 '추출물'은 추출용매를 처리하여 얻은 조추출물뿐만 아니라 혼합 추출물의 가공물도 포함한다. 예를 들어, 혼합 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The term 'extract' in this specification includes not only crude extracts obtained by processing an extraction solvent, but also processed products of mixed extracts. For example, the mixed extract can be prepared in powder form by additional processes such as reduced pressure distillation and freeze-drying or spray drying.
또한, 본 발명의 추출물은 광의로는 동물에게 투여할 수 있도록 제형화된 혼합 추출물의 가공물, 예컨대, 분말도 포함하는 의미를 갖는다. 비록 본 발명에서 추출물로 실험을 진행하긴 하였으나, 추출물의 가공물과 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상 가능할 것이다.In addition, the extract of the present invention, in a broad sense, also includes processed products of mixed extracts formulated to be administered to animals, such as powder. Although experiments were conducted with extracts in the present invention, those skilled in the art would be able to predict that the desired effect can be achieved even in the form of processed extracts.
한편, 본 명세서에서 용어 '유효성분으로 포함하는'이란 혼합 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 일예로, 상기 혼합 추출물은 10 내지 1500 ㎍/㎖, 바람직하게는 100 내지 1000 ㎍/㎖의 농도로 사용된다. 혼합 추출물은 혼합 추출물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 혼합 추출물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.Meanwhile, in this specification, the term 'including as an active ingredient' means containing a sufficient amount to achieve the efficacy or activity of the mixed extract. For example, the mixed extract is used at a concentration of 10 to 1500 ㎍/㎖, preferably 100 to 1000 ㎍/㎖. Since the mixed extract has no side effects on the human body even when administered in excessive amounts, the upper quantitative limit of the mixed extract contained in the composition of the present invention can be selected within an appropriate range by a person skilled in the art.
본 발명의 치매는 알츠하이머성 치매, 혈관성 치매, 루이체 치매, 전측두엽 치매, 파킨슨병 치매, 헌팅턴병 치매, 정상압 뇌 수두증에 의한 치매 및 두부외상에 의한 치매로 이루어진 군으로부터 선택되는 어느 하나 이상의 치매일 수 있고, 특히, 본 발명의 치매는 알츠하이머성 치매를 예방, 개선 또는 치료하는 것일 수 있다.Dementia of the present invention refers to any one or more dementias selected from the group consisting of Alzheimer's dementia, vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, Huntington's disease dementia, dementia due to normal pressure hydrocephalus, and dementia due to head trauma. In particular, the dementia of the present invention may prevent, improve, or treat Alzheimer's dementia.
본 발명에 따른 식품 조성물은 하기 약학 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention can be formulated in the same manner as the pharmaceutical composition below and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, and health supplements. etc.
본 발명의 식품 조성물은 유효성분으로서 혼합 추출물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 번혼합 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may contain not only mixed extracts as active ingredients, but also ingredients commonly added during food production, including, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a flavoring agent, natural flavoring agents [thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)] and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is manufactured as a drink or beverage, citric acid, high fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be additionally included in addition to the mixed extract of the present invention. .
한편 상기 혼합 추출물을 유효성분으로 하는 식품 조성물은 단독으로 "인지기능 장애 예방 또는 개선에 도움을 주는 건강기능식품"으로 이용될 수 있고, "기억력 증진에 도움을 주는 건강기능식품", "기억력 강화에 도움을 주는 건강기능식품" 또는 "인지기능 또는 기억력 개선에 도움을 주는 건강기능식품"으로 이용될 수 있다.Meanwhile, the food composition containing the above mixed extract as an active ingredient can be used alone as a “health functional food that helps prevent or improve cognitive dysfunction,” “a health functional food that helps improve memory,” and “enhancement of memory.” It can be used as a “health functional food that helps improve cognitive function or memory” or “a health functional food that helps improve cognitive function or memory.”
상기 '건강기능식품'은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 법적 기준에 따라 제조(가공을 포함)한 식품(건강기능식품에 관한 법률 제3조 제1호)을 말한다. 상기 '건강기능식품'은 국가마다 용어나 범위에 차이가 있을 수 있으나, 미국의 '식이 보충제(Dietary Supplement)', 유럽의 '식품 보충제(Food Supplemnet)', 일본의 '보건기능식품' 또는 '특정보건용식품(Food for Special Health Use, FoSHU)', 중국의 '보건식품' 등에 해당할 수 있다.The above ‘health functional food’ refers to food manufactured (including processing) in accordance with legal standards using raw materials or ingredients with functional properties useful to the human body (Article 3, Paragraph 1 of the Health Functional Food Act). The terminology or scope of the above 'health functional food' may vary depending on the country, but it is also called 'Dietary Supplement' in the United States, 'Food Supplement' in Europe, 'Health Functional Food' or 'Health Functional Food' in Japan. It may be classified as ‘Food for Special Health Use (FoSHU)’ or ‘Health Food’ in China.
상기 식품 조성물 또는 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, 식품첨가물로서의 적합여부는 다른 규정이 없는 한 '식품첨가물공전'의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 따른다.The above food composition or health functional food may additionally contain food additives, and its suitability as a food additive is determined by the specifications and standards for the relevant item in accordance with the general provisions of the ‘Food Additive Code’ and general test methods, etc., unless otherwise specified. Follow.
또한 상기 건강기능식품에는 상기 혼합 추출물과 함께 기억력 증진, 인지기능 장애 예방 또는 개선 및 치매 예방 또는 개선과 관련된 건강기능식품 소재를 복합하여 사용할 수 있다.In addition, the health functional food may be used in combination with the mixed extract and health functional food ingredients related to memory enhancement, prevention or improvement of cognitive dysfunction, and prevention or improvement of dementia.
또한, 본 발명은 혼합 추출물을 유효성분으로 포함하는 치매 예방 또는 개선용 약학 조성물을 제공한다.Additionally, the present invention provides a pharmaceutical composition for preventing or improving dementia comprising a mixed extract as an active ingredient.
본 발명의 약학 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention can be prepared using pharmaceutically suitable and physiologically acceptable auxiliaries in addition to the active ingredients, and the auxiliaries include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, and lubricants. Agents or flavoring agents can be used.
상기 약학 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약학 조성물로 바람직하게 제제화할 수 있다.For administration, the pharmaceutical composition may be preferably formulated as a pharmaceutical composition containing one or more pharmaceutically acceptable carriers in addition to the active ingredients described above.
상기 약학 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. Additionally, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacance or sodium oleate, sodium stearate, magnesium stearate, sodium Includes benzoate, sodium acetate, sodium chloride, etc. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.Acceptable pharmaceutical carriers for compositions formulated as liquid solutions include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these ingredients can be mixed and used, and other common additives such as antioxidants, buffers, and bacteriostatic agents can be added as needed. In addition, diluents, dispersants, surfactants, binders, and lubricants can be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and in case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., and is preferably oral administration.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약학 조성물의 1일 투여량은 0.001-10 g/㎏이다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and is usually A skilled doctor can easily determine and prescribe an effective dosage for desired treatment or prevention. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g/kg.
본 발명의 약학 조성물은 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention can be prepared in unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient, or can be prepared by placing it in a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, or capsule, and may additionally contain a dispersant or stabilizer.
또한, 본 발명은 치매 개선 또는 치료용 의약 또는 식품의 제조를 위한 혼합 추출물의 용도를 제공한다. 상기한 바와 같이 혼합 추출물은 치매 치료 또는 개선을 위한 용도로 이용될 수 있다.Additionally, the present invention provides the use of the mixed extract for the production of medicine or food for improving or treating dementia. As mentioned above, the mixed extract can be used to treat or improve dementia.
또한, 본 발명은 포유동물에게 유효량의 혼합 추출물을 투여하는 것을 포함하는 치매의 개선, 예방 또는 치료 방법을 제공한다.Additionally, the present invention provides a method for improving, preventing, or treating dementia comprising administering an effective amount of mixed extract to a mammal.
여기에서 사용된 용어 "포유동물"은 치료, 관찰 또는 실험의 대상인 포유동물을 말하며, 바람직하게는 인간을 말한다.As used herein, the term “mammal” refers to a mammal, preferably a human, that is the subject of treatment, observation or experiment.
여기에서 사용된 용어 "유효량"은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학 조성물의 양을 의미하는 것으로, 이는 해당 질환 또는 장애의 증상의 완화를 유도하는 양을 포함한다. 본 발명의 유효 성분에 대한 유효량 및 투여횟수는 원하는 효과에 따라 변화될 수 있다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 본 발명의 예방, 치료 또는 개선 방법에 있어서, 성인의 경우, 추출물을 1일 1회 내지 수회 투여시, 0.001 g/kg 내지 10 g/kg의 용량으로 투여하는 것이 바람직하다.As used herein, the term "effective amount" means the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal, or human, as believed by a researcher, veterinarian, physician, or other clinician, to cause the disease in question. or an amount that induces relief of symptoms of the disorder. The effective amount and frequency of administration of the active ingredient of the present invention may vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by a person skilled in the art, and can be determined based on the type of disease, the severity of the disease, the content of the active ingredient and other ingredients contained in the composition, the type of dosage form, and the patient's age, weight, and general health. It can be adjusted according to various factors, including condition, gender and diet, administration time, administration route and secretion rate of the composition, treatment period, and concurrently used drugs. In the prevention, treatment or improvement method of the present invention, for adults, it is preferable to administer the extract at a dose of 0.001 g/kg to 10 g/kg once or several times a day.
본 발명의 치료방법에서 혼합 추출물을 유효 성분으로 포함하는 조성물은 경구, 직장, 정맥내, 동맥내, 복강내, 근육내, 흉골내, 경피, 국소, 또는 피내 경로를 통해 통상적인 방식으로 투여할 수 있다.In the treatment method of the present invention, the composition containing the mixed extract as an active ingredient can be administered in a conventional manner through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, or intradermal routes. You can.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.Hereinafter, preferred embodiments are presented to aid understanding of the present invention. However, the following examples are merely illustrative of the present invention, and it is clear to those skilled in the art that various changes and modifications are possible within the scope and spirit of the present invention. It is natural that such variations and modifications fall within the scope of the attached patent claims.
실시예 1 : 혼합 추출물 제조Example 1: Preparation of mixed extract
건조 분쇄된 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프씨드, 대추, 천궁, 숙지황 및 감초를 하기 표 1에 따라 혼합한 후, 각각 정제수와 에탄올의 부피비 30:70으로 혼합한 70% 에탄올을 가하고(분쇄된 시료 중량의 10배), 60℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초의 혼합 추출물(동결건조 분말)을 45%의 수율로 수득하였다.Dried and crushed Maekmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice were mixed according to Table 1 below, and then mixed with purified water and ethanol at a volume ratio of 30:70. 70% ethanol was added (10 times the weight of the ground sample), and extraction was performed by heating at 60°C for 6 hours. The extract was filtered, concentrated under reduced pressure to remove ethanol, and then freeze-dried to produce a 45% yield of mixed extracts (freeze-dried powder) of Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheonung, Rehmannia glutinosa, and licorice. was obtained.
이때, 상기 햄프씨드는 전처리를 통해 오일성분을 제거한 것으로, 햄프씨드를 헥산으로 추출한 후, 오일성분이 제거된 햄프씨드 잔사물일 수 있다. 구체적으로 헴프씨드 1 중량을 기준으로 10배의 헥산(hexane)을 첨가하여 10,000 rpm으로 10분 동안 균질화하고, 실온에서 180 rpm으로 5시간 동안 교반한 다음, 12,000 rpm으로 10분 동안 원심분리하여 상등액(오일 성분)을 제거하고, pellet(잔사)만 회수하였다. 회수한 오일성분이 제거된 햄프씨드의 잔사를 30 ℃에서 24시간 동안 건조시킨 후 사용하였다.At this time, the hemp seeds have had their oil components removed through pretreatment, and may be hemp seed residues from which the oil components have been removed after extracting the hemp seeds with hexane. Specifically, 10 times the weight of hexane was added based on the weight of 1 hemp seed, homogenized at 10,000 rpm for 10 minutes, stirred at room temperature for 5 hours at 180 rpm, and then centrifuged at 12,000 rpm for 10 minutes to obtain a supernatant. (Oil component) was removed, and only the pellet (residue) was recovered. The recovered hemp seed residue from which the oil component was removed was dried at 30°C for 24 hours before use.
실시예 2 : 혼합 추출물(+검실) 제조Example 2: Preparation of mixed extract (+gumsil)
상기 실시예 1과 동일하게 제조된 혼합 추출물 100 중량부에 대하여 검실 추출물을 5 중량부 혼합하여 혼합 추출물(+검실)을 제조하였다.A mixed extract (+gumsil) was prepared by mixing 5 parts by weight of gumsil extract with 100 parts by weight of the mixed extract prepared in the same manner as in Example 1.
상기 검실 추출물은 다음과 같이 제조된 것을 사용하였다. 우선 국내산 가시연꽃의 씨를 분쇄한 분말과 70% 에탄올 수용액을 1 : 10의 중량비로 혼합하여 50 ℃에서 16시간동안 추출하여 검실 에탄올 추출물을 수득하였다. 상기 수득된 추출물은 여과 및 감압 농축을 거쳐 동결건조로 분말화하여 이용하였다.The gumsil extract was prepared as follows. First, the powder of pulverized domestic prickly lotus seeds and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 50°C for 16 hours to obtain a gumsil ethanol extract. The obtained extract was filtered, concentrated under reduced pressure, and powdered by freeze-drying for use.
비교예 1 내지 5 : 혼합 추출물 제조Comparative Examples 1 to 5: Preparation of mixed extract
건조 분쇄된 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프씨드, 대추, 천궁, 숙지황 및 감초를 하기 표 2에 따라 혼합한 후, 각각 정제수를 가하고(분쇄된 시료 중량의 10배) 100℃로 6시간 동안 가온추출하였다. 추출액을 여과하고 감압농축하여 에탄올을 제거한 다음 동결건조하여 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프시드, 대추, 천궁, 숙지황 및 감초의 혼합 추출물(동결건조 분말)을 36.4%의 수율로 수득하였다.After mixing dried and crushed Maekmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, Angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and Licorice root according to Table 2 below, purified water was added to each (10 times the weight of the crushed sample) ) Extraction was performed by heating at 100°C for 6 hours. The extract was filtered, concentrated under reduced pressure to remove ethanol, and then freeze-dried to produce a mixed extract (freeze-dried powder) of Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa, and licorice root, with a yield of 36.4%. was obtained.
이때, 상기 햄프씨드는 전처리를 통해 오일성분을 제거한 것을 사용하였다. 구체적으로 헴프씨드 1 중량을 기준으로 10배의 헥산(hexane)을 첨가하여 10,000 rpm으로 10분 동안 균질화하고, 실온에서 180 rpm으로 5시간 동안 교반한 다음, 12,000 rpm으로 10분 동안 원심분리하여 상등액(오일 성분)을 제거하고, pellet(잔사)만 회수하였다. 회수한 오일성분이 제거된 햄프씨드의 잔사를 30 ℃에서 24시간 동안 건조시킨 후 사용하였다.At this time, the hemp seeds were used from which the oil component was removed through pretreatment. Specifically, 10 times the weight of hexane was added based on the weight of 1 hemp seed, homogenized at 10,000 rpm for 10 minutes, stirred at room temperature for 5 hours at 180 rpm, and then centrifuged at 12,000 rpm for 10 minutes to obtain a supernatant. (Oil component) was removed, and only the pellet (residue) was recovered. The recovered hemp seed residue from which the oil component was removed was dried at 30°C for 24 hours before use.
비교예 6 : 혼합 열수 추출물 제조Comparative Example 6: Preparation of mixed hot water extract
에탄올 수용액 대신 100 ℃의 정제수를 사용하였다는 것을 제외하고 모두 실시예 1과 동일하게 제조하였다.Everything was prepared in the same manner as in Example 1, except that purified water at 100°C was used instead of the ethanol aqueous solution.
실험예 1: 생체 외 실험Experimental Example 1: In vitro experiment
실험예 1-1: PC12 Adh cell의 배양Experimental Example 1-1: Culture of PC12 Adh cells
PC12 신경세포(KCLB 21721, Korean Cell Line Bank, Seoul, Korea)는 rat의 부신 수질(adrenal medulla)에 발생한 크롬친화세포종(pheochromocytoma)에서 유래된 세포주로 신경세포의 특성을 갖는 세포이다. PC12 Adh cell이 75cm2 플라스크에서 High media(FBS + Horse serum + 4.5g/㎖ glucose DMEM)에 접종하여 37℃, 5% CO2 incubator에서 배양하였다. Media는 cell이 실험을 위한 충분한 양이 되기까지 2~3일에 한번씩 교체해 주었다. cell 양이 약 70%가 되는 것을 확인 후 cell을 75cm2 플라스크에서 10cm2 플레이트로 옮겨 준 후 High media (Horse serum 500㎕, Penicillin 500㎕ in 50㎖ 4.5g/㎖ glucose DMEM)에 NGF(neuron growth factor) 2.5㎕를 처리하여 뉴런의 길이가 cell의 길이의 약 1~2배가 되는 것을 관찰하였다.PC12 neuronal cells (KCLB 21721, Korean Cell Line Bank, Seoul, Korea) are cell lines derived from pheochromocytoma occurring in the adrenal medulla of rats and are cells with neuronal characteristics. PC12 Adh cells were inoculated into high media (FBS + horse serum + 4.5g/ml glucose DMEM) in a 75cm 2 flask and cultured in a 5% CO 2 incubator at 37°C. Media was replaced every 2 to 3 days until the cells were sufficient for the experiment. After confirming that the cell amount was about 70%, the cells were transferred from a 75cm 2 flask to a 10cm 2 plate and then incubated with NGF (neuron growth) in high media (Horse serum 500㎕, Penicillin 500㎕ in 50㎖ 4.5g/㎖ glucose DMEM). factor), it was observed that the length of the neuron became about 1 to 2 times the length of the cell by treating 2.5㎕.
실험예 1-2: 세포 생존율 분석Experimental Example 1-2: Cell viability analysis
10cm2 플레이트에서 cell을 긁어내어 원심분리(2000rpm, 5min at RT)하여 4 X 104개의 cell이 200㎕ 안에 있도록 하여 96 well 플레이트에 일정하게 분주하여 Low media(Horse serum 500㎕, Penicillin 500㎕ in 1.0g/㎖ glucose DMEM)에 실시예 1-3 및 비교예 1-9의 혼합 추출물을 50 ㎍/㎖의 농도로 각각 처리하고 1시간이 지난 후 베타아밀로이드(Aβ25-35, 15 μM)를 처리하였다. 3일 동안 배양한 후 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide, SIGMA, USA)를 1mg/㎖의 농도로 PBS에 희석한 MTT solution을 100 ㎕ 분주한 뒤 3시간 동안 37℃, 5% CO2 incubator에서 방치하였다. 3시간 경과 후 상층액을 버리고 DMSO(Dimethyl Sulfoxide, SIGMA, USA) 100㎕를 분주하고 10분간 상온에서 방치한 뒤 microplate reader(680, bio-rad, Tokyo, Japan)에서 570 nm에서 측정하여 세포 생존율을 확인하였다. 세포 생존율은 대조구(control)에 대한 %로 나타내었다. 상술한 혼합 추출물은 PBS 완충액을 처리하여 용해하였고, 동일양의 PBS 완충액을 대조구(control)로 이용하였고, 베타아밀로이드(Aβ25-35, 15 μM)가 처리된 대조구는 베타아밀로이드(Aβ25-35, 15 μM)처리 control로 별도 표기하였다. 실험예 1에 따른 세포 생존율 분석 결과를 표 3에 나타내었다.Scrape the cells from the 10cm 2 plate and centrifuge (2000rpm, 5min at RT) so that 4 1.0 g/mL glucose DMEM) was treated with the mixed extracts of Examples 1-3 and Comparative Examples 1-9 at a concentration of 50 μg/mL, and after 1 hour, beta-amyloid (Aβ 25-35 , 15 μM) was added. Processed. After culturing for 3 days, dispense 100 ㎕ of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide, SIGMA, USA) diluted in PBS at a concentration of 1 mg/ml. Then, it was left in an incubator at 37°C and 5% CO 2 for 3 hours. After 3 hours, the supernatant was discarded, 100㎕ of DMSO (Dimethyl Sulfoxide, SIGMA, USA) was dispensed, left at room temperature for 10 minutes, and cell viability was measured at 570 nm in a microplate reader (680, bio-rad, Tokyo, Japan). was confirmed. Cell viability was expressed as % relative to the control. The above-described mixed extract was dissolved by treatment with PBS buffer, and the same amount of PBS buffer was used as a control. The control treated with beta-amyloid (Aβ 25-35 , 15 μM) was treated with beta-amyloid (Aβ 25-35 , 15 μM). , 15 μM) was separately indicated as a treatment control. The results of cell viability analysis according to Experimental Example 1 are shown in Table 3.
표 3에 따르면, PC12 신경세포에 베타아밀로이드(Aβ25-35)가 처리된 경우, 처리되지 않은 경우보다 생존율이 32% 유의하게 감소되었음을 확인할 수 있었다. 즉 베타아밀로이드(Aβ25-35, 15 μM)를 처리함으로써 신경독성이 유도된 것을 확인하였다. 본 발명에 따른 혼합 추출물 처리군(실시예 1, 2)은 베타아밀로이드로 인한 신경독성에 대해 우수한 보호효과를 가진다는 것을 확인할 수 있다. 구체적으로 실시예 1의 혼합 추출물 처리군은 Aβ25-35 대조군에 비해 세포생존율이 33% 유의적으로 증가하였고, 실시예 2의 혼합 추출물 처리군은 Aβ25-35 대조군에 비해 37% 유의하게 증가함을 확인할 수 있었다.According to Table 3, when PC12 neurons were treated with beta-amyloid (Aβ 25-35 ), it was confirmed that the survival rate was significantly reduced by 32% compared to the untreated case. That is, it was confirmed that neurotoxicity was induced by treatment with beta-amyloid (A β25-35 , 15 μM). It can be confirmed that the mixed extract treatment group according to the present invention (Examples 1 and 2) has an excellent protective effect against neurotoxicity caused by beta-amyloid. Specifically, the cell survival rate of the mixed extract treated group in Example 1 significantly increased by 33% compared to the Aβ 25-35 control group, and the mixed extract treated group of Example 2 significantly increased by 37% compared to the Aβ 25-35 control group. It was confirmed that this was the case.
반면, 본 발명의 혼합 추출물에서 어느 하나라도 함량이 과도하게 증가하거나 낮아진 경우, 또는 원지, 백복신, 초석잠, 강황, 당귀, 햄프씨드, 천궁이 1:1:1:1:1:1:1의 중량비로 존재하지 않는 경우, 숙지황과 감초가 1:1의 비율이 아닌 경우(비교예 1-5)에는 혼합 추출물 처리군(실시예 1, 2)보다 25~35% 이상 감소하였다. On the other hand, if the content of any one of the mixed extracts of the present invention is excessively increased or decreased, or if the content of Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, and Cheongungi is 1:1:1:1:1:1:1 When not present in a weight ratio of , when the ratio of Rehmannia glutinosa and Licorice root was not 1:1 (Comparative Examples 1-5), it decreased by more than 25 to 35% compared to the mixed extract treatment group (Examples 1 and 2).
또한, 본 발명의 혼합물을 70% 에탄올 수용액이 아닌 열수로 추출한 경우에도 30~37% 이상 감소한 것을 확인하였다. In addition, it was confirmed that the mixture of the present invention was reduced by more than 30-37% even when extracted with hot water rather than 70% ethanol aqueous solution.
상술한 실험을 통해 본 발명에 따른 혼합 추출물 특히, 검실 추출물이 포함된 혼합 추출물(실시예 2)은 신경독성물질인 베타아밀로이드에 의한 신경세포 사멸을 억제함으로써 신경세포를 보호하는 것으로 판단된다. 결국 상술한 결과를 고려할 때, 본 발명에 따른 혼합 추출물의 신경세포 보호 효과는 치매의 예방, 개선 또는 치료에 우수한 효과를 달성할 수 있다.Through the above-described experiment, it was determined that the mixed extract according to the present invention, especially the mixed extract containing gum extract (Example 2), protects nerve cells by inhibiting nerve cell death caused by beta-amyloid, a neurotoxic substance. Ultimately, considering the above-mentioned results, the neuronal protective effect of the mixed extract according to the present invention can achieve an excellent effect in preventing, improving, or treating dementia.
실험예 2: 치매 동물모델에서의 혼합 추출물 처리에 따른 기억력 개선 효과 확인Experimental Example 2: Confirmation of memory improvement effect according to mixed extract treatment in dementia animal model
실험예 2-1: 치매 동물모델의 준비Experimental Example 2-1: Preparation of dementia animal model
실험동물은 Sprague-Dawley 종을 이용하였으며, 6주령의 수컷을 대한바이오링크 사에서 구입하여 표준사료로 일주일 동안 사육실의 환경에 적응시킨 후 임의로 각 군당 8마리씩 11군으로 나누어 실험에 사용하였다. 식이와 물은 자유섭취방법으로 급여하였으며, 실험실의 사육조건은 온도 20±2 ℃, 습도 50±5%, 명암은 12시간(08:00∼20:00)을 주기로 자동 조절하여 유지하였다.The Sprague-Dawley species was used as the experimental animal, and 6-week-old males were purchased from Daehan Biolink, fed with standard feed, adapted to the environment of the breeding room for a week, and then randomly divided into 11 groups with 8 animals per group for use in the experiment. Diet and water were provided ad libitum, and the laboratory breeding conditions were maintained at a temperature of 20 ± 2 ℃, humidity of 50 ± 5%, and light and dark automatically adjusted every 12 hours (08:00 to 20:00).
기억력 개선 효과를 확인하기 위하여, 수동회피실험과 Y자 미로 실험 및 수중 미로실험을 수행하기 위해 다음과 같이 각 군을 준비하였다.In order to confirm the effect of improving memory, each group was prepared as follows to perform a passive avoidance experiment, a Y-maze experiment, and a water maze experiment.
실험군 1은 실시예 1의 혼합 추출물을 100 mg/kg의 용량으로 1일 1회 총 1주 동안 경구투여한 것이고, 실험군 2는 실시예 2의 혼합 추출물을 각각 100 mg/kg의 용량으로 1일 1회 총 1주 동안 경구투여하여 제조한 것이다. 비교군은 비교예 6의 추출물을 100 mg/kg의 용량으로 각각 1일 1회 총 1주 동안 경구투여한 것이다. 음성 대조군(CON)은 Saline 100 mg/kg의 용량으로 1일 1회 총 1주 동안 경구투여한 것이다. 각 군은 행동실험 시작하기 30분 전에 기억손상 유도를 위한 scoplamine(Sigma, S1875, 2 mg/kg, i.p.)을 복강 내 주사로 투여하였다.Experimental group 1 was orally administered the mixed extract of Example 1 at a dose of 100 mg/kg once a day for a total of 1 week, and experimental group 2 was administered the mixed extract of Example 2 at a dose of 100 mg/kg each day. It is manufactured by oral administration once for a total of 1 week. The comparison group was orally administered the extract of Comparative Example 6 at a dose of 100 mg/kg once a day for a total of 1 week. The negative control group (CON) was administered orally with Saline at a dose of 100 mg/kg once a day for a total of 1 week. Each group was administered scoplamine (Sigma, S1875, 2 mg/kg, i.p.) by intraperitoneal injection to induce memory impairment 30 minutes before the start of the behavioral experiment.
정상군(NOR)은 scoplamine을 포함하는 약물을 전혀 투여하지 않은 정상 동물모델이다.The normal group (NOR) is a normal animal model that was not administered any drugs, including scoplamine.
실험예 2-2: 수동 회피 실험 (Passive avoidance test)Experimental Example 2-2: Passive avoidance test
수동회피 반응 실험은 다음과 같이 수행하였다. Passive avoidance test 기계를 이용하여 A room과 B room 으로 나누어진 기계를 이용하였으며 A room에 실험동물을 넣은 후 60초간 적응 시간을 준 뒤 5분 동안 A room에는 빛과 소음이 발생하게 하여 실험동물에게 스트레스를 주도록 하였다. 빛과 소음이 발생하는 동안 B room으로 통하는 통로가 열리게 되며 실험동물이 스트레스를 피하고자 B room으로 이동하게 되면 통로가 닫히고 0.5mA의 전류가 3초 동안 지지대는 발 부위에 흐르도록 하였다. 첫 실험이 진행된 후 2시간 뒤에 같은 실험을 반복하여 기억하도록 하고 24시간 뒤 실험동물이 B room으로 이동 여부와 이동하는 데까지 걸린 시간을 측정하였다.The passive avoidance response experiment was performed as follows. Using a passive avoidance test machine, the machine was divided into A room and B room. After placing the experimental animals in room A, they were given an adaptation time of 60 seconds, and then light and noise were generated in room A for 5 minutes to give the experimental animals It was made to be stressful. While light and noise were generated, the passage to room B was opened, and when the experimental animal moved to room B to avoid stress, the passage was closed and a current of 0.5 mA was allowed to flow through the foot area of the support for 3 seconds. Two hours after the first experiment was conducted, the same experiment was repeated and memorized, and 24 hours later, whether the experimental animals moved to room B and the time it took to move were measured.
이와 같은 수동 회피 실험은 실험 대상의 단기 기억능력을 확인하기 위한 실험으로 소음과 빛으로 스트레스를 유발하는 A room과 소음과 빛은 없지만 전기 자극이 있는 B room으로 나누어진 기계에서 A room에 있는 실험 대상이 B room의 전기 자극을 기억의 여부를 관찰하기 위하여 B room으로 넘어가는데 까지 걸린 시간을 관찰하였으며 300초까지 측정하였다. 그 결과를 도 1에 나타냈다. This passive avoidance experiment is an experiment to check the subject's short-term memory ability. An experiment is conducted in room A on a machine divided into room A, which induces stress with noise and light, and room B, which has no noise and light but has electrical stimulation. In order to observe whether the subject remembered the electrical stimulation of room B, the time it took for the subject to move to room B was observed and measured up to 300 seconds. The results are shown in Figure 1.
각 실험결과는 평균 ± 표준편차(mean ± standard deviation)로 나타내었고, 통게 분석은 일원배치 분산분석법(ANOVA)을 실시하였으며, Tukey's HSD(honest significant difference) post hoc test를 통해 사후검정을 하였으며, p<0.01 미만의 경우 통계적으로 유의한 것으로 판정하였다.The results of each experiment were expressed as mean ± standard deviation, and statistical analysis was performed using one-way analysis of variance (ANOVA). Post hoc testing was performed using Tukey's honest significant difference (HSD) post hoc test, p If it was less than <0.01, it was judged to be statistically significant.
도 1은 실험군 1, 2 및 비교군의 수동회피실험 결과 그래프이다(* p<0.01 compared with NOR group, # p<0.01 compared with CON group). 이에 따르면, 스코폴라민 투여시 마우스는 밝은 방(A)에 머무르는 시간이 짧아 인지기능이 감소함을 보여주었다. 실시예 1의 혼합 추출물을 투여한 경우, 그 자체만으로 음성대조군과 비교하여 현저한 개선효과를 나타내었다(1.92배). 특히 실시예 2의 혼합 추출물 투여는 음성대조군(CON) 대비 2.24배 이상의 현저한 개선효과를 갖는 것으로 확인되었다. 본 발명의 실시예 1 내지 2의 혼합 추출물 투여는 스코폴라민 투여로 인해 저하된 인지기능을 정상군 가깝게 회복시켜 주는 것을 확인하였다. 콜린성 기능 장애와 산화적 스트레스로 인한 치매를 유의적으로 억제함을 확인할 수 있다.Figure 1 is a graph of the results of the passive avoidance experiment of experimental groups 1 and 2 and the comparison group (* p <0.01 compared with NOR group, # p <0.01 compared with CON group). According to this, when scopolamine was administered, the mouse stayed in the bright room (A) for a short time, showing a decrease in cognitive function. When the mixed extract of Example 1 was administered, it showed a significant improvement (1.92 times) compared to the negative control group by itself. In particular, it was confirmed that administration of the mixed extract of Example 2 had a significant improvement effect of more than 2.24 times compared to the negative control group (CON). It was confirmed that administration of the mixed extract of Examples 1 and 2 of the present invention restored cognitive function deteriorated due to scopolamine administration to a level close to that of the normal group. It can be confirmed that it significantly suppresses dementia caused by cholinergic dysfunction and oxidative stress.
반면, 본 발명의 혼합물을 70% 에탄올 수용액이 아닌 열수로 추출한 비교군(비교예 6의 추출물)은 음성대조군(CON) 대비 유의한 효과가 관찰되지 않았다. 즉 수동회피실험을 통해, 본 발명에 따른 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프씨드, 대추, 천궁, 숙지황 및 감초의 혼합 추출물은 스코폴라민에 의해 손상된 인지기능을 정상군에 가까운 수준으로 회복시킨 바, 콜린성 신경계 작용을 통한 학습 및 기억력 회복 및 개선에 크게 도움을 주는 것을 확인되었다.On the other hand, no significant effect was observed in the comparison group (extract of Comparative Example 6) in which the mixture of the present invention was extracted with hot water rather than 70% ethanol aqueous solution compared to the negative control group (CON). That is, through a passive avoidance experiment, the mixed extract of Maekmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice according to the present invention normalized cognitive function damaged by scopolamine. When it was restored to a level close to that of the group, it was confirmed that it greatly helped in recovering and improving learning and memory through the action of the cholinergic nervous system.
실험예 2-3: 수중 미로 실험 (Water maze)Experimental Example 2-3: Water maze experiment
지름이 140 cm, 높이가 45 cm인 원형수조 안에 물을 약 70% 채우고 우유를 넣어 안이 들여다 보이지 않도록 하였다. 지름이 15 cm, 높이가 35 cm인 원형 플랫폼을 수면 아래 1.5 cm가 되도록 물 높이를 조절하였으며, 물의 온도는 21~ 32℃ 가 되도록 하였다. 미로주위를 어둡게 하고 50 W 빛을 비춰주었다. 이와 같은 수중 미로 실험은 실험 대상의 공간학습 및 기역력을 알아보기 위한 것이다. A circular tank with a diameter of 140 cm and a height of 45 cm was filled with about 70% water and milk was added so that the inside could not be seen. The water level was adjusted to be 1.5 cm below the water surface on a circular platform with a diameter of 15 cm and a height of 35 cm, and the water temperature was set to 21 to 32°C. The area around the maze was darkened and 50 W light was illuminated. This underwater maze experiment is intended to determine the spatial learning and cognitive abilities of the test subjects.
Training trial: 각 군의 동물을 수조에 넣어서 플랫폼에 도달하는 시간을 90초 동안 하였다. 90초 내에 플랫폼을 찾지 못하면 꺼내어 플랫폼에 올려놓고 15초 동안 방치한 후, 30초 뒤에 수조에 넣고 플랫폼에 도달하는 시간을 기록하였다. 1 일 2회씩(오전, 오후로 나누어 실시) 실시하며 15초 내에 플랫폼에 도달하게 되면 training trial이 완료된 것으로 간주하였다. Training trial: Animals from each group were placed in a water tank and had 90 seconds to reach the platform. If the platform was not found within 90 seconds, it was taken out, placed on the platform, left for 15 seconds, then placed in a water tank 30 seconds later, and the time to reach the platform was recorded. It was conducted twice a day (in the morning and afternoon), and the training trial was considered completed when it reached the platform within 15 seconds.
training이 완료된 후, 정상군(NOR), 음성대조군(CON)(scopolamine 2 mg/kg 단독 투여군), 실험군 1, 2(scopolamine 2 mg/kg과 실시예 1, 2 100 mg/kg를 각각 투여한 군) 및 비교군(scopolamine 2 mg/kg과 비교예 6 100 mg/kg를 모두 투여한 군)으로 나누어 각 군에 대하여 escape time을 측정하였다. 1일 2회씩 5일 동안 측정 하였으며, 측정방법은 training trial 방법과 동일하며 최대 측정 시간은 90 초로 하였다. 그 결과를 도 2에 나타내었다. After training was completed, the normal group (NOR), the negative control group (CON) (scopolamine 2 mg/kg administered alone), and experimental groups 1 and 2 (scopolamine 2 mg/kg and Examples 1 and 2 100 mg/kg were administered, respectively). group) and a comparison group (a group administered both scopolamine 2 mg/kg and Comparative Example 6 100 mg/kg), and the escape time was measured for each group. Measurements were made twice a day for 5 days. The measurement method was the same as the training trial method, and the maximum measurement time was 90 seconds. The results are shown in Figure 2.
각 실험결과는 평균 ± 표준편차(mean ± standard deviation)로 나타내었고, 통게 분석은 일원배치 분산분석법(ANOVA)을 실시하였으며, Tukey's HSD(honest significant difference) post hoc test를 통해 사후검정을 하였으며, p<0.01 미만의 경우 통계적으로 유의한 것으로 판정하였다.The results of each experiment were expressed as mean ± standard deviation, and statistical analysis was performed using one-way analysis of variance (ANOVA). Post hoc testing was performed using Tukey's honest significant difference (HSD) post hoc test, p If it was less than <0.01, it was judged to be statistically significant.
도 2는 실험군 1, 2 및 비교군의 수중미로시험 결과 그래프이다(* p<0.01 compared with NOR group, # p<0.01 compared with CON group). 도 2에 따르면 스코폴라민으로 기억이 손상된 음성대조군(CON)은 정상군(NOR)에 대하여 통계적으로 유의적으로 excape latency 시간이 증가하였다. 이는 장기기억과 관련된 학습능력이 감소되었음을 의미한다. 본 발명에 따른 혼합 추출물이 투여된 실험군 1 및 실험군 2의 excape 시간이 가장 많이 감소하였으며, 특히 실험군 2에서 시간이 가장 유의하게 감소한 경향을 확인할 수 있다. 이를 통해 본 발명에 따른 맥문동, 석창포, 원지, 백복신, 초석잠, 강황, 당귀, 햄프씨드, 대추, 천궁, 숙지황 및 감초의 혼합 추출물은 치매 동물모델의 장기기억 개선에 효과가 뛰어난 것을 알 수 있다.Figure 2 is a graph of the water maze test results of experimental groups 1 and 2 and the comparison group (* p <0.01 compared with NOR group, # p <0.01 compared with CON group). According to Figure 2, the negative control group (CON), whose memory was impaired by scopolamine, had a statistically significant increase in excape latency time compared to the normal group (NOR). This means that learning ability related to long-term memory has been reduced. The escape time of experimental group 1 and experimental group 2 administered with the mixed extract according to the present invention decreased the most, and in particular, the time showed the most significant decrease in experimental group 2. Through this, it can be seen that the mixed extract of Maekmundong, Seokchangpo, Wonji, Baekboksin, Choseokjam, turmeric, angelica root, hemp seed, jujube, Cheongung, Rehmannia glutinosa and licorice according to the present invention is effective in improving long-term memory in animal models of dementia. .
이상, 본 발명의 실시예들에 대하여 설명하였으나, 해당 기술 분야에서 통상의 지식을 가진 자라면 특허청구범위에 기재된 본 발명의 사상으로부터 벗어나지 않는 범위 내에서, 구성 요소의 부가, 변경, 삭제 또는 추가 등에 의해 본 발명을 다양하게 수정 및 변경시킬 수 있을 것이며, 이 또한 본 발명의 권리범위 내에 포함된다고 할 것이다.Although the embodiments of the present invention have been described above, those skilled in the art can add, change, delete or add components without departing from the spirit of the present invention as set forth in the patent claims. The present invention may be modified and changed in various ways, and this will also be included within the scope of rights of the present invention.
하기에 본 발명의 혼합 추출물을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Below, a formulation example of a composition containing the mixed extract of the present invention is described, but the present invention is not intended to be limited, but merely explained in detail.
제제예 1. 산제의 제조Formulation Example 1. Preparation of powder
실시예 1 또는 실시예 2에서 얻은 혼합 추출물; 500 mgMixed extract obtained in Example 1 or Example 2; 500mg
유당 100 mg100 mg lactose
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled into an airtight bubble to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
실시예 1 또는 실시예 2에서 얻은 혼합 추출물; 300 mgMixed extract obtained in Example 1 or Example 2; 300mg
옥수수전분 100 mgCorn starch 100 mg
유당 100 mg100 mg lactose
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are manufactured by compressing them according to a typical tablet manufacturing method.
제제예 3. 캅셀제의 제조Formulation Example 3. Preparation of capsules
실시예 1 또는 실시예 2에서 얻은 혼합 추출물; 200 mgMixed extract obtained in Example 1 or Example 2; 200mg
결정성 셀룰로오스 3 mg3 mg crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.Capsules are prepared by mixing the above ingredients and filling them into gelatin capsules according to a typical capsule manufacturing method.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injections
실시예 1 또는 실시예 2에서 얻은 혼합 추출물; 600 mgMixed extract obtained in Example 1 or Example 2; 600mg
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mgSterile distilled water for injection 2974 mg
Na2HPO4,12H2O 26 mgNa2HPO4,12H2O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.It is prepared with the above ingredients per ampoule according to the usual manufacturing method for injections.
제제예 5. 액제의 제조Formulation Example 5. Preparation of liquid formulation
실시예 1 또는 실시예 2에서 얻은 혼합 추출물; 4 gMixed extract obtained in Example 1 or Example 2; 4g
이성화당 10 g10 g isomerized sugar
만니톨 5 g5 g mannitol
정제수 적량Proper amount of purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체 100g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.According to the usual liquid preparation method, add and dissolve each ingredient in purified water, add an appropriate amount of lemon flavor, mix the above ingredients, add purified water to adjust the total to 100g, fill in a brown bottle, and sterilize to prepare the liquid. .
제제예 6. 과립제의 제조Formulation Example 6. Preparation of granules
실시예 1 또는 실시예 2에서 얻은 혼합 추출물; 1,000 mgMixed extract obtained in Example 1 or Example 2; 1,000 mg
비타민 혼합물 적량Vitamin mixture dosage
비타민 A 아세테이트 70 ㎍Vitamin A acetate 70 μg
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 ㎍Vitamin B12 0.2 ㎍
비타민 C 10 mgVitamin C 10 mg
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 mgNicotinamide 1.7 mg
엽산 50 ㎍Folic acid 50 μg
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture appropriate amount
황산제1철 1.75 mgFerrous sulfate 1.75 mg
산화아연 0.82 mgZinc oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgMonobasic Potassium Phosphate 15 mg
제2인산칼슘 55 mgDibasic calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mgCalcium carbonate 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.The composition ratio of the above vitamin and mineral mixture is a mixture of ingredients relatively suitable for granules in a preferred embodiment, but the mixing ratio may be modified arbitrarily. After mixing the above ingredients according to a normal granule manufacturing method, the granules are formed. It can be prepared and used to manufacture a health functional food composition according to a conventional method.
제제예 7. 기능성 음료의 제조Formulation Example 7. Preparation of functional beverage
실시예 1 또는 실시예 2에서 얻은 혼합 추출물; 1,000 mgMixed extract obtained in Example 1 or Example 2; 1,000 mg
구연산 1,000 mg1,000 mg citric acid
올리고당 100 g100 g oligosaccharides
매실농축액 2 g2 g plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 mLAdd purified water to make a total of 900 mL.
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. After mixing the above ingredients according to a typical health drink manufacturing method, stirring and heating at 85°C for about 1 hour, the resulting solution was filtered, placed in a sterilized 2 L container, sealed, sterilized, stored in the refrigerator, and then refrigerated. Used for manufacturing the functional beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.The composition ratio is a preferred embodiment of mixing ingredients that are relatively suitable for beverages of preference, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as demand class, demand country, and intended use.
Claims (6)
상기 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것을 특징으로 하는 치매 예방 또는 개선용 식품 조성물.According to paragraph 1,
A food composition for preventing or improving dementia, wherein the extract is extracted with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 식품 조성물은, 혼합 추출물 총 중량에 대하여 15~25 중량% 맥문동, 10~15 중량% 석창포, 5~7 중량% 원지, 5~7 중량% 백복신, 5~7 중량% 초석잠, 5~7 중량% 강황, 5~7 중량% 당귀, 5~7 중량% 햄프시드, 8~10 중량% 대추, 5~7 중량% 천궁, 5~10 중량% 숙지황 및 5~10 중량% 감초로 혼합된 것을 특징으로 하는 치매 예방 또는 개선용 식품 조성물.According to paragraph 1,
The food composition contains 15-25% by weight of Macmundong, 10-15% by weight of Seokchangpo, 5-7% by weight of Wonji, 5-7% by weight of Baekboksin, 5-7% by weight of Chosukjam, 5-7% by weight, based on the total weight of the mixed extract. % by weight turmeric, 5-7% by weight angelica, 5-7% by weight hemp seed, 8-10% by weight jujube, 5-7% by weight Cheonggung, 5-10% by weight Rehmannia glutinosa and 5-10% by weight licorice. A food composition for preventing or improving dementia.
상기 식품 조성물에서 햄프씨드는, 햄프씨드를 헥산으로 추출한 후, 오일성분이 제거된 햄프씨드 잔사물인 것을 특징으로 하는 치매 예방 또는 개선용 식품 조성물.According to paragraph 1,
A food composition for preventing or improving dementia, characterized in that the hemp seeds in the food composition are hemp seed residues from which oil components have been removed after extracting hemp seeds with hexane.
상기 식품 조성물은, 혼합 추출물 100 중량부에 대하여 1 내지 5 중량부의 검실(Euryale ferox Salisbury) 추출물을 더 포함하는 것을 특징으로 하는 치매 예방 또는 개선용 식품 조성물.According to paragraph 1,
The food composition is a food composition for preventing or improving dementia, characterized in that it further comprises 1 to 5 parts by weight of Euryale ferox Salisbury extract based on 100 parts by weight of the mixed extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220151526A KR20240074940A (en) | 2022-11-14 | 2022-11-14 | Compositon comprising Liriope platyphylla as an active ingredient for improving and treating dementia disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220151526A KR20240074940A (en) | 2022-11-14 | 2022-11-14 | Compositon comprising Liriope platyphylla as an active ingredient for improving and treating dementia disease |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240074940A true KR20240074940A (en) | 2024-05-29 |
Family
ID=91277808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220151526A KR20240074940A (en) | 2022-11-14 | 2022-11-14 | Compositon comprising Liriope platyphylla as an active ingredient for improving and treating dementia disease |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240074940A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100871559B1 (en) | 2008-11-05 | 2008-12-01 | 원광대학교산학협력단 | The healthy and funtional foods comprising the extracts from herb medicines for the improvements and prevention of the symptoms in the dementia |
-
2022
- 2022-11-14 KR KR1020220151526A patent/KR20240074940A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100871559B1 (en) | 2008-11-05 | 2008-12-01 | 원광대학교산학협력단 | The healthy and funtional foods comprising the extracts from herb medicines for the improvements and prevention of the symptoms in the dementia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101328668B1 (en) | Compositon with anti-obesity and anti-diabetic activity comprising cudrania tricuspidata and adlay, and use thereof | |
JP2021008447A (en) | Health keeping product composition applicable to adult female, elderly, and sub-healthy people | |
KR101817055B1 (en) | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities | |
JP2016523897A (en) | Composition having function of alleviating premenstrual syndrome and menstrual pain | |
CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR102099147B1 (en) | Composition for preventing, ameliorating or treating obesity comprising Heracleum moellendorffii root and Torilis japonica mixed extract as effective component | |
KR101673204B1 (en) | Health beverage using natural materials with protection of brain cells | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR101698869B1 (en) | A composition for treatment of Atopic dermatitis containing oriental medicine herbs | |
KR20240074940A (en) | Compositon comprising Liriope platyphylla as an active ingredient for improving and treating dementia disease | |
KR102050554B1 (en) | Composition for hangover treatment and manufacturing method for the same | |
KR20200061285A (en) | Food Composition for blood circulation and for Preventing blood vessel disease Comprising Extract of Galangal | |
KR102675725B1 (en) | Herbal pill composition for anti-inflammatory and immune enhancement containing Paeonia lactiflora and Cinnamomum cassia Blume and its preparation method | |
KR102496864B1 (en) | Anti-obesity composition containing extract of Paliurus ramosissimus as an active ingredient | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
KR20190103665A (en) | Food composition for improving or preventing obesity containing extract of saururus chinensis | |
KR102552842B1 (en) | Functional food composition containing the fermented natural extracts and the process for the preparation thereof | |
KR102195980B1 (en) | Fermentation pills and its manufacturing method | |
KR102234225B1 (en) | Pharmaceutical Composition Comprising Extracts of Eucommia ulmoides Oliver and Achyranthes japonica for Preventing or Treating Obesity | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
KR102590587B1 (en) | Anti-obesity composition comprising cirsium japonicum extract as effective component | |
KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
KR102185006B1 (en) | A composition for improving, preventing and treating of asthma and vascular disease | |
KR102016646B1 (en) | Composition for preventing, ameliorating or treating obesity comprising Rudbeckia laciniata and Torilidis Fructus mixed extract as effective component |